CD274 and neoplasm: At present, more and more biomarkers have been used to predict the efficacy of immunotherapy, including programmed death protein ligand-1 (PD-L1), blood-based tumor mutation burden (bTMB), microsatellite instability (MSI), DNA damage repair (DDR), tumor-infiltrating lymphocytes (TILs), etc. [14, 15].